Charles Schwab Investment Management Inc. Boosts Stock Position in Stereotaxis, Inc. (NYSEAMERICAN:STXS)

Charles Schwab Investment Management Inc. boosted its stake in shares of Stereotaxis, Inc. (NYSEAMERICAN:STXS) by 10.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 167,297 shares of the company’s stock after acquiring an additional 15,491 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.20% of Stereotaxis worth $341,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. SG Americas Securities LLC acquired a new stake in Stereotaxis in the third quarter valued at about $39,000. Forum Financial Management LP acquired a new stake in shares of Stereotaxis in the 2nd quarter valued at approximately $48,000. Rhumbline Advisers boosted its stake in shares of Stereotaxis by 645.6% in the second quarter. Rhumbline Advisers now owns 48,251 shares of the company’s stock valued at $88,000 after buying an additional 41,780 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Stereotaxis by 247.5% during the second quarter. Bank of New York Mellon Corp now owns 189,592 shares of the company’s stock worth $345,000 after acquiring an additional 135,041 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in Stereotaxis by 46.2% during the second quarter. Renaissance Technologies LLC now owns 488,700 shares of the company’s stock worth $889,000 after acquiring an additional 154,400 shares during the period. 45.35% of the stock is currently owned by hedge funds and other institutional investors.

Stereotaxis Price Performance

Stereotaxis stock opened at $2.22 on Friday. The firm has a market capitalization of $188.10 million, a price-to-earnings ratio of -7.93 and a beta of 1.57. Stereotaxis, Inc. has a one year low of $1.66 and a one year high of $3.29.

Stereotaxis (NYSEAMERICAN:STXS) last released its quarterly earnings data on Monday, November 11th. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). Stereotaxis had a negative return on equity of 162.54% and a negative net margin of 85.79%. The company had revenue of $9.20 million for the quarter, compared to analysts’ expectations of $6.80 million. On average, analysts predict that Stereotaxis, Inc. will post -0.26 earnings per share for the current year.

Stereotaxis Company Profile

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.